Ideaya Biosciences (United States)

Recent papers from Ideaya Biosciences (United States)

1. Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
2. Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025Pigment Cell & Melanoma Research · 2026
3. A Quantitative Efflux Ratio-Integrated Model for Passive PermeabilityEstimation from Caco-2 AssaysDrug Metabolism and Bioanalysis · 2026
4. Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.Journal of Clinical Oncology · 2026
5. IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted ( MTAP -Del) advanced solid tumors (IDE892001): Phase 1 trial.Journal of Clinical Oncology · 2026
6. Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.Journal of Clinical Oncology · 2026
7. TCFH-NMI: An Emerging Method for Amide Bond Formation and BeyondOrganic Process Research & Development · 2026
8. Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083Clinical Infectious Diseases · 2026
9. Abstract 4505: IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAPdel cancers in combination with the allosteric MAT2A inhibitor IDE397.Cancer Research · 2026
10. Abstract 4483: The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications.Cancer Research · 2026
11. Optimization of Incubation Time for Accurate Protein Binding Assessment in Biological Matrices using Equilibrium DialysisDrug Metabolism and Bioanalysis · 2026
12. I Wish I Had Known That! Impactful Guidance and Perspectives for a Fulfilling Career in ToxicologyInternational Journal of Toxicology · 2025
13. Drug Interaction Studies of Cabamiquine:Ganaplacide Combination against Hepatic Plasmodium bergheiACS Infectious Diseases · 2024
14. Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept studyPLoS ONE · 2024
15. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous NephropathyKidney International Reports · 2024
16. A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.Journal of Clinical Oncology · 2024
17. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 TrialJTO Clinical and Research Reports · 2024
18. Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer CellsCancer Discovery · 2024
19. Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study2023
20. Successful Adjunctive Treatment of Bilateral Diffuse Uveal Melanocytic Proliferation With High-Dose Intravenous Immunoglobulin TherapyRetinal Cases & Brief Reports · 2023